Key Points
- COO Anish Patel sold 6,663 shares on Dec. 8 at an average price of $21.02 for proceeds of $140,056.26, and now directly owns 263,311 shares — a 2.47% drop in his stake valued at about $5.53 million.
- Patel has been selling multiple recent tranches, including 6,667 shares on Nov. 7 at $17.40 and 6,667 shares on Oct. 7 at $20.10, signaling a pattern of ongoing insider sales.
- For context, ELVN has a market cap of about $1.18 billion, a 52‑week range of $13.30–$25.37, and an average analyst rating of "Moderate Buy" with a mean price target of $41.20.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,663 shares of the company's stock in a transaction on Monday, December 8th. The shares were sold at an average price of $21.02, for a total value of $140,056.26. Following the completion of the transaction, the chief operating officer directly owned 263,311 shares in the company, valued at approximately $5,534,797.22. This represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Anish Patel also recently made the following trade(s):
- On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $17.40, for a total value of $116,005.80.
- On Tuesday, October 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.10, for a total transaction of $134,006.70.
Enliven Therapeutics Stock Performance
ELVN stock opened at $19.92 on Thursday. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $25.37. The company has a market capitalization of $1.18 billion, a PE ratio of -10.77 and a beta of 0.35. The company's 50-day simple moving average is $20.86 and its 200 day simple moving average is $20.43.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Enliven Therapeutics during the first quarter valued at approximately $60,000. BNP Paribas Financial Markets boosted its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at $96,000. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock valued at $106,000 after purchasing an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS raised its holdings in shares of Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock worth $136,000 after buying an additional 2,500 shares in the last quarter. 95.08% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
ELVN has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $41.20.
Read Our Latest Analysis on ELVN
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
